# RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT

> **NCT05858814** · PHASE1,PHASE2 · RECRUITING · sponsor: **Guangdong Ruishun Biotech Co., Ltd** · enrollment: 72 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** RC1012 injection (allo-DNT cells)

## Key facts

- **NCT ID:** NCT05858814
- **Lead sponsor:** Guangdong Ruishun Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-04
- **Primary completion:** 2024-05-27
- **Final completion:** 2026-06-24
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2023-05-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05858814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05858814, "RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05858814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*